686344-29-6
686344-29-6 結(jié)構(gòu)式
基本信息
1-[9-(4-氯苯基)-8-(2-氯苯基)-9H-嘌呤-6-基]-4-乙基氨基哌啶-4-甲酰胺
otenabant
Otenabant, >=98%
CP945598 free base
Otenabant (CP-945,598)
CP 945598
OTENABANT
CP945598
CP 945598
CP-945598
CP945598
Otenabant (CP-945598 free base)
1-[9-(4-Chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxamide
4-Piperidinecarboxamide, 1-[8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl]-4-(ethylamino)-
物理化學(xué)性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2024/11/08 | HY-10871 | 奧替那班 Otenabant | 686344-29-6 | 5mg | 500元 |
| 2024/11/08 | HY-10871 | 奧替那班 Otenabant | 686344-29-6 | 10mM * 1mLin DMSO | 561元 |
| 2024/11/08 | HY-10871 | 奧替那班 Otenabant | 686344-29-6 | 10mg | 800元 |
常見問題列表
Ki: 0.7 nM (CB1)
Otenabant HCl has low affinity with K i of 7.6 μM for human CB2 receptors. Otenabant HCl inhibits CB1 receptor with moderate unbound microsomal clearance, low hERG affinity, and adequate CNS penetration.
Otenabant acutely stimulates energy expenditure in rats and decreases the respiratory quotient indicating a metabolic switch to increased fat oxidation. Otenabant (10 mg/kg, p.o.) promotes a 9%, vehicle adjusted weight loss in a 10 day weight loss study in diet-induced obese mice. Otenabant HCl reverses four cannabinoid agonistmediated behaviors (locomotor activity, hypothermia, analgesia, and catalepsy) following administration of the synthetic CB1 receptor agonist CP-55940. Otenabant HCl exhibits dose-dependent anorectic activity in a model of acute food intake in rodents and increased energy expenditure and fat oxidation.